Leap Therapeutics, Inc.

The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col

While biopharma executives, investors and deal-makers are busy presenting at the J.P. Morgan Healthcare Conference in San Francisco, global political attention is fixating on a deal signed thousands o

Synthetic biology specialist Intrexon Corp. has shifted its focus exclusively to health care and is selling its agricultural, industrial and other biotechnology businesses. Going forward, Intrexon’s

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . BeiGene Picks Up Asia Rights